ONCS has been the topic of several other reports. Zacks Investment Research raised shares of OncoSec Medical from a “sell” rating to a “hold” rating in a research note on Tuesday. BTIG Research lowered their price target on shares of OncoSec Medical from $10.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, March 16th.
OncoSec Medical stock opened at $0.77 on Friday. The stock has a market cap of $30.30 million, a P/E ratio of -0.74 and a beta of 2.03. OncoSec Medical has a 12 month low of $0.67 and a 12 month high of $4.25. The company’s fifty day simple moving average is $0.97 and its 200-day simple moving average is $1.06.
Several institutional investors have recently added to or reduced their stakes in ONCS. Susquehanna International Group LLP lifted its position in shares of OncoSec Medical by 62.7% in the fourth quarter. Susquehanna International Group LLP now owns 44,075 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 16,990 shares in the last quarter. Geode Capital Management LLC raised its position in shares of OncoSec Medical by 7.1% in the fourth quarter. Geode Capital Management LLC now owns 262,478 shares of the biotechnology company’s stock valued at $251,000 after purchasing an additional 17,467 shares during the period. HighTower Advisors LLC bought a new position in shares of OncoSec Medical in the third quarter valued at about $45,000. Tocqueville Asset Management L.P. grew its stake in shares of OncoSec Medical by 86.8% in the third quarter. Tocqueville Asset Management L.P. now owns 49,500 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 23,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new position in shares of OncoSec Medical in the third quarter valued at about $53,000. Institutional investors own 13.98% of the company’s stock.
OncoSec Medical Company Profile (Get Rating)
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.
- Get a free copy of the StockNews.com research report on OncoSec Medical (ONCS)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.